Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week randomized double-blind placebo-controlled phase 3 trial of dapagliflozin monotherapy in Japanese adults with type 2 diabetes
jRCT2080221432Phase 3
- Sponsor
- AstraZeneca
- Start
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080221432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221432.